Skip to main content

QUESTION: I have a 42yo female patient with anxiety/depression and lots of COMT/MAO SNPs. She recently was put on Cymbalta and it is working really well. This surprised me because I would expect a norepinephrine re-uptake inhibitor to potentially exacerbate her anxiety if she has more trouble metabolizing catecholamines. Can you shed any light on this?

ANSWER: It is an SSNRI so the “S” effect is winning. Often in the SSNRI the “S” is the bigger effector anyway

You may also find this webcall helpful.

Dr. Paul Anderson

Paul S. Anderson is a naturopathic physician, Medical Director & Founder of Anderson Medical Specialty Associates (AMSA). He is a recognized authority in the field of integrative cancer research and the treatment of chronic diseases, genomic conditions, and auto-immune and infectious disorders.